Lisa Wellinger

Title: Lisa Wellinger: Innovator in Antibody Development

Introduction

Lisa Wellinger is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of biotechnology, particularly in the development of antibodies. Her work focuses on improving the efficacy and safety of therapeutic antibodies.

Latest Patents

Wellinger holds a patent for "Antibodies targeting ActRIIA and ActRIIB." This patent describes antibodies and antibody fragments that are specific for ActRIIA and ActRIIB. The antibodies are enhanced versions of bimagrumab, featuring improved affinity against ActRIIA. This advancement translates into better in vitro potency and efficacy, along with an improved pharmacokinetic (PK) and pharmacodynamic (PD) profile. Additionally, these antibodies exhibit higher stability, making them suitable for subcutaneous (s.c.) administration. Some of the antibodies also carry Fc modifications, ensuring safety for prolonged treatments.

Career Highlights

Wellinger is currently associated with Six Peaks Bio AG, where she continues her innovative work in antibody research. Her career is marked by a commitment to advancing therapeutic options in the medical field.

Collaborations

Wellinger collaborates with notable colleagues, including Christian Kunz and Amélie Wiederkehr, who contribute to her research endeavors.

Conclusion

Lisa Wellinger is a key figure in the development of advanced therapeutic antibodies, with her innovative work promising to enhance treatment options for various medical conditions. Her contributions to biotechnology are noteworthy and continue to impact the field positively.